STAT Plus: Pharmalittle: Sackler role in opioid crisis to be debated in court; J&J legal strategy shows risks
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is topped off with a visit to our oldest Pharmalot ancestor, who turns another page on the calendar, hanging with our short people, and catching up on our napping. And what about you? Once again, we will note this is a fine time to enjoy the great outdoors — apples and pumpkins are beckoning. You could read a good book or make time for someone special. And if you feel adventurous, tweet your support for the Hong Kong protesters and see what happens. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …
How much members of the Sackler family should be held accountable for the role their company, Purdue Pharma, played in the opioid crisis will be at the center of a hearing Friday in federal bankruptcy court, the Associated Press informs us. State attorneys general are evenly divided over whether to accept terms offered by Purdue to settle some 2,600 claims against it. About half of them say the proposed deal is too lenient to family members who siphoned billions out of their privately held company and stashed much of it overseas.
Continue to STAT Plus to read the full story…
